Construction and detection method of a zebrafish heart failure model

By using aristolochic acid to treat nppb:luc or cmmlc2:GFP transgenic zebrafish embryos, the zebrafish heart failure model was constructed, which solved the problem of insufficient construction efficiency and reliability of the existing technology central failure model, and achieved rapid heart development and function Abnormal detection, suitable for high-throughput drug screening.

CN112271000BActive Publication Date: 2024-11-22SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202011175134.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-10-28
Publication Date
2024-11-22
Estimated Expiration
2040-10-28

AI Technical Summary

Technical Problem

The existing zebrafish heart failure model construction methods are not efficient and reliable enough, it is difficult to quickly complete the detection of cardiac development and functional abnormalities, and there is a lack of effective tools suitable for high-throughput drug screening.

Method used

By treating nppb:luc or cmc2:GFP transgenic zebrafish embryos with aristolochic acid, it increases the expression of the heart failure marker nppb, interferes with heart development and reduces survival, thus constructing a zebrafish heart failure model and in animals and at the organizational level, perform expression analysis to achieve rapid construction and detection.

Benefits of technology

The constructed model induces heart failure within 72 hours after fertilization of zebrafish, with high stability and repetition, and is suitable for high-throughput drug screening and analysis of myocardial protection or cardiotoxicity-related drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112271000B_ABST
    Figure CN112271000B_ABST
Patent Text Reader

Abstract

The invention discloses a construction and detection method of a zebrafish heart failure model. The cmlc2:GFP transgenic zebrafish couples a green fluorescent protein reporter gene to the downstream of the cmlc2 promoter, so that the zebrafish heart with green fluorescence can be observed under a fluorescence microscope; the nppb:luc transgenic zebrafish couples a luciferase reporter gene to the downstream of the nppb promoter, and the expression level of nppb is identified by the luciferase value. The zebrafish embryos of the two transgenic nppb:luc or cmlc2:GFP are treated with AA to increase the expression of the heart failure marker gene nppb, thereby interfering with the heart development of the zebrafish and reducing its survival rate, thereby constructing a zebrafish heart failure model. The model constructed by the invention induces zebrafish heart failure 72 hours after zebrafish fertilization, and simultaneously performs heart development and expression analysis of heart failure marker genes at the zebrafish animal level and tissue level, and can quickly complete the construction and analysis of the heart failure model; the model has high stability and good repeatability, and can be applied to high-throughput drug screening and analysis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medicine, and in particular to a construction and detection method of a zebrafish heart failure model. Background Art

[0002] Zebrafish is an important vertebrate model organism. Zebrafish embryos are transparent and develop rapidly. Zebrafish have a high degree of genetic similarity with humans and have cardiovascular, nervous and metabolic systems similar to mammals. Compared with traditional model organisms, zebrafish have unique advantages in cardiovascular diseases. Zebrafish are fertilized in vitro, develop in vitro, and have a fast heart development rate. The heart of zebrafish embryos begins to beat 24 hours after fertilization (24hpf), completes heart cyclization 48 hours after fertilization (48hpf), forms an S-shaped heart, and completes cardiac chamber differentiation 72 hours after fertilization (72hpf). Abnormalities in cardiac morphology and function can be detected in living zebrafish embryos. Wild-type zebrafish embryos exposed to small molecule compounds have a high correlation with human toxicity reactions and play an important role in drug toxicity research.

[0003] Aristolochic acid (AA), also known as total aristolochic acid and phagocytic acid, is a type of nitrophenanthrene organic acid found in natural products, with a wide range of pharmacological effects, such as enhancing cellular immunity, anti-tumor, antibacterial, anti-platelet aggregation, etc. There are dozens of Chinese herbal medicines containing aristolochic acid, such as Aristolochic acid, Asarum, Radix Stephaniae, Radix Aristolochiae, and Asarum. Studies have reported that aristolochic acid has clear nephrotoxicity and may also be an important factor in inducing liver cancer. Therefore, many countries have strict regulations on the use of drugs containing aristolochic acid. The present application uses aristolochic acid to treat nppb:luc and cmlc2:GFP zebrafish embryos, resulting in an increase in the expression of the heart failure marker gene nppb, interfering with the heart development of zebrafish and reducing its survival rate, thereby establishing a zebrafish heart failure model. The model established by the present invention is efficient, reliable and simple. The establishment and analysis of the heart failure model can be completed 3 days after zebrafish fertilization. It is suitable for high-throughput drug screening and is of great significance for finding drugs related to myocardial protection or cardiotoxicity. Summary of the invention

[0004] The purpose of the present invention is to provide a method for constructing and detecting a zebrafish heart failure model. By treating two transgenic zebrafish embryos, nppb:luc or cmlc2:GFP, with AA, the expression level of the heart failure marker gene nppb is increased, the heart development of the zebrafish is interfered with and the survival rate is reduced, thereby constructing a zebrafish heart failure model. The constructed model induces zebrafish heart failure 72 hours after zebrafish fertilization, and at the same time, the expression of heart development and heart failure marker genes is analyzed at the zebrafish animal level and tissue level, so that the construction and analysis of the heart failure model can be completed quickly; the model has high stability and good repeatability, and can be applied to high-throughput drug screening and analysis.

[0005] The purpose of the present invention can be achieved through the following technical solutions:

[0006] A zebrafish heart failure model is constructed. The cmlc2:GFP transgenic zebrafish has a green fluorescent protein reporter gene coupled to the downstream of the cmlc2 promoter, so that the zebrafish heart with green fluorescence can be observed under a fluorescence microscope; the nppb:luc transgenic zebrafish has a luciferase reporter gene coupled to the downstream of the nppb promoter, and the expression level of nppb is marked by the luciferase value. The zebrafish embryos of the two transgenic nppb:luc or cmlc2:GFP are treated with AA, resulting in an increase in the expression of the heart failure marker gene nppb, which interferes with the heart development of the zebrafish and reduces its survival rate, thereby constructing a zebrafish heart failure model. The construction method of the model is as follows:

[0007] S1. Determination of zebrafish developmental stages;

[0008] S2, drug treatment: the microplate was set up into two experimental groups, namely the drug treatment group and the control group;

[0009] S3, heart failure analysis using zebrafish cardiomyopathy model;

[0010] S4. Analysis of zebrafish heart development;

[0011] S5. Analyze the survival rate of zebrafish.

[0012] Furthermore, in step S1, the parents of transgenic zebrafish of the nppb:luc or cmlc2:GFP strains are respectively selected for mating and hatching, and zebrafish at 24 hpf are selected and transferred into corresponding microplates, and marked for differentiation.

[0013] Furthermore, in the drug treatment group, AA powder was dissolved in DMSO solution to prepare a 10 mM AA storage concentration, 1 μL of 10 mM AA was added to a zebrafish microplate containing 1 mL of fish water, and the zebrafish were treated with the drug. At this time, the treatment concentration of the drug AA was 10 μM.

[0014] Furthermore, the control group was treated with a DMSO solution of the same concentration as that of the drug-treated group.

[0015] Furthermore, the drug-treated group and the control group were both added with the same volume of fish culture water and cultured at the same constant temperature.

[0016] Furthermore, the heart failure analysis in step S3 is to treat the nppb:luc strain zebrafish with drugs to 72hpf, add luciferase reagent to each well of the microplate, incubate in the dark, measure the luciferase value, and observe the expression level of the heart failure marker gene nppb.

[0017] Furthermore, the analysis of heart development in step S4 is to treat cmlc2:GFP strain zebrafish with drugs until 72 hpf, anesthetize the zebrafish, and observe the heart morphology of the zebrafish under a fluorescence microscope.

[0018] Furthermore, the survival rate analysis in step S5 is to observe the heartbeat of the zebrafish under a microscope after treating the cmlc2:GFP strain zebrafish with drugs to 96 hpf, and to calculate the survival rate of the zebrafish.

[0019] A detection method for constructing a zebrafish heart failure model, the detection method:

[0020] T1, cmlc2:GFP zebrafish were treated with drugs until 72 hpf, and the zebrafish hearts were isolated;

[0021] T2. Extract RNA, reverse transcribe it into cDNA, and then perform fluorescence quantitative PCR to detect the mRNA expression levels of heart failure marker genes nppa, nppb and IL-1β.

[0022] Beneficial effects of the present invention:

[0023] 1. The model constructed by the present invention induces zebrafish heart failure 72 hours after fertilization, and simultaneously performs expression analysis of cardiac development and heart failure marker genes at the zebrafish animal level and tissue level, which can quickly complete the construction and analysis of the heart failure model;

[0024] 2. The present invention has high stability and good repeatability and can be applied to high-throughput drug screening and analysis. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The present invention will be further described below in conjunction with the accompanying drawings.

[0026] Figure 1 This is a schematic diagram of the expression of the heart failure marker gene nppb in zebrafish nppb:luc of the present invention;

[0027] Figure 2This is a schematic diagram of the effect of AA of the present invention on the cardiac development of cmlc2:GFP zebrafish;

[0028] Figure 3 is a statistical graph of the survival rate of zebrafish after AA treatment of the present invention;

[0029] Figure 4 It is a schematic diagram of the expression level of the heart failure gene in the cmlc2:GFP zebrafish heart after AA treatment of the present invention. DETAILED DESCRIPTION

[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] A zebrafish heart failure model is constructed. The cmlc2:GFP transgenic zebrafish has a green fluorescent protein reporter gene coupled to the downstream of the cmlc2 promoter, so that the zebrafish heart with green fluorescence can be observed under a fluorescence microscope; the nppb:luc transgenic zebrafish has a luciferase reporter gene coupled to the downstream of the nppb promoter, and the expression level of nppb is marked by the luciferase value. The zebrafish embryos of the two transgenic nppb:luc or cmlc2:GFP are treated with AA (aristolochic acid), resulting in an increase in the expression of the heart failure marker gene nppb, which interferes with the heart development of the zebrafish and reduces its survival rate, thereby constructing a zebrafish heart failure model. The construction method of the model is as follows:

[0032] S1. Determination of zebrafish developmental stage: Take the transgenic zebrafish parents of nppb:luc or cmlc2:GFP strains, mate and hatch them, select zebrafish at 24 hpf, transfer them to the corresponding microplates, and mark them to distinguish them;

[0033] S2. Drug treatment: Set the microplate into two experimental groups: drug treatment group and control group:

[0034] S21, drug treatment group: AA powder was dissolved in DMSO solution to prepare a 10mM AA stock concentration, 1uL of 10mM AA was added to a zebrafish microplate containing 1mL of fish water, and the zebrafish were treated with drugs. At this time, the treatment concentration of drug AA was 10μM;

[0035] S22, control group: zebrafish embryos were treated with DMSO solution of the same concentration as that of the drug-treated group;

[0036] Both groups were added with the same volume of fish culture water and cultured at the same temperature;

[0037] S3. Heart failure analysis using zebrafish cardiomyopathy model: After drug treatment of nppb:luc strain zebrafish to 72 hpf, add luciferase reagent to each well of the microplate, incubate in the dark, measure the luciferase value, and observe the expression level of heart failure marker gene nppb;

[0038] S4. Analysis of zebrafish heart development: cmlc2:GFP strain zebrafish were treated with drugs until 72 hpf, the zebrafish were anesthetized, and the zebrafish heart morphology was observed under a fluorescence microscope;

[0039] S5. Analysis of zebrafish survival rate: After cmlc2:GFP strain zebrafish were treated with drugs until 96 hpf, the heartbeat of the zebrafish was observed under a microscope and the survival rate of the zebrafish was calculated.

[0040] A detection method for constructing a zebrafish heart failure model

[0041] T1. RNA extraction: After cmlc2:GFP strain zebrafish were treated with drugs until 72 hpf, the zebrafish hearts were isolated and RNA was extracted;

[0042] T2. Detect the expression of heart failure-related markers in zebrafish hearts: The extracted RNA was reverse transcribed into cDNA, and fluorescent quantitative PCR was performed to detect the expression levels of mRNA of heart failure marker genes nppa, nppb and IL-1β. The primer sequences are as follows:

[0043]

[0044]

[0045] Example 1: Zebrafish culture

[0046] Transgenic zebrafish were cultured according to a standardized protocol, with a water temperature of 28.5°C and a light-to-dark cycle ratio of 14 h:10 h. Embryos were collected one hour after adult zebrafish spawning and cultured in E3 hatching medium (containing 0.2925 g NaCl, 0.01267 g KCl, 0.03663 g CaCl2, and 0.0396 g MgSO4 per 1 L deionized water). The developmental stage of embryos and larvae was represented by hours post-fertilization (hpf).

[0047] When zebrafish embryos developed to 24 hpf, 0.003% 1-phenyl-2-thiourea (PTU, Sigma) was added to the E3 incubation medium to inhibit the production of melanin, and the zebrafish embryos were cultured to 72 hpf or 96 hpf.

[0048] Example 2: Detection of nppb luciferase value in zebrafish heart failure model treated with AA

[0049] 24 hpf zebrafish embryos nppb:luc were transferred to a 96-well culture plate, 100 μL E3 incubation solution was added to each well, AA or control DMSO was added to make the final concentration of 10 μM, and the plate was cultured in a 28°C incubator.

[0050] When the zebrafish embryos developed to 72 hpf, 25 μL of luciferase reagent was added to each well, protected from light, and incubated at room temperature for 60 minutes before luciferase assay.

[0051] Since there is a firefly luciferase reporter gene downstream of the nppb promoter, the expression of nppb was displayed by detecting the luciferase value.

[0052] The results showed that compared with the DMSO control group, the AA treatment group caused a significant increase in the expression of BNP in zebrafish embryos. Figure 1 .

[0053] Example 3: Effects of AA on zebrafish heart development and survival rate

[0054] 24 hpf zebrafish embryos tg(cmlc2:GFP) were transferred to a 12-well plate, AA (concentration 10 μM) or control DMSO was added, and the plates were cultured in a 28°C incubator. After 48 hours, 72 hpf zebrafish larvae were anesthetized with tricainemethanesulfonate (Sigma), embedded in 2.5% methyl cellulose (Sigma), and photographed under a fluorescence microscope.

[0055] The results showed that the effects of AA on zebrafish heart development were mainly manifested in pericardial edema, cardiac cyclization defects, and abnormal position of the ventricle and atrium. Figure 2 .

[0056] To further confirm the effect of AA on zebrafish heart development, the survival rate of 96hpf zebrafish larvae was counted.

[0057] The results showed that compared with the DMSO control group, the survival rate of zebrafish in the AA treatment group was significantly reduced. Figure 3 .

[0058] Example 4: Detection of the expression of heart failure-related genes in zebrafish after AA treatment

[0059] 24 hpf zebrafish embryos (cmlc2:GFP) treated with AA (10 μM) or DMSO were collected, and 72 hpf zebrafish embryos were collected 48 hours later. The zebrafish hearts were isolated and the green hearts were collected under a fluorescence microscope.

[0060] RNA was extracted with trizol and reverse transcribed into cDNA. Fluorescence quantitative PCR was performed to detect the mRNA expression levels of heart failure marker genes nppa, nppb and IL-1β.

[0061] The PCR reaction conditions were as follows: pre-denaturation at 95°C for 30 s, denaturation at 95°C for 10 s, annealing and extension at 60°C for 30 s, 40 cycles of denaturation at 95°C for 10 s, annealing and extension at 60°C for 10 s, denaturation at 95°C for 15 s, melting curve, and the reaction was carried out using a Bio-rad fluorescent quantitative PCR instrument.

[0062] The results showed that compared with the DMSO control group, the AA treatment group caused a significant increase in the mRNA expression levels of heart failure-related genes nppa, nppb, and IL-1β in zebrafish hearts. Figure 4 .

[0063] Combination Figure 1 , Figure 3 , Figure 4 It was found that the BNP expression level, survival rate and heart failure-related gene expression in zebrafish embryos treated with AA in the experimental group were significantly different from those in the control group.

[0064] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0065] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.

Claims

1. A method for constructing a zebrafish heart failure model. It is characterized in that The cmlc2:GFP transgenic zebrafish coupled the green fluorescent protein reporter gene to the downstream of the cmlc2 promoter, so that the zebrafish heart with green fluorescence can be observed under a fluorescence microscope; the nppb:luc transgenic zebrafish coupled the luciferase reporter gene to the downstream of the nppb promoter, and the luciferase value was used to identify the expression level of nppb. The zebrafish embryos with nppb:luc or cmlc2:GFP transgenes were treated with AA, which increased the expression of the heart failure marker gene nppb, interfered with the heart development of the zebrafish and reduced its survival rate, thereby constructing a zebrafish heart failure model. The steps of constructing the model are as follows: S1. Determination of zebrafish developmental stages; S2, drug treatment: the microplate was set up into two experimental groups, namely the drug treatment group and the control group; S3, heart failure analysis using zebrafish cardiomyopathy model; S4. Analysis of zebrafish heart development; S5. Analyze the survival rate of zebrafish; In the step S1, the parents of transgenic zebrafish of the nppb:luc or cmlc2:GFP strains are respectively selected for mating and hatching, and zebrafish at 24 hpf are selected and transferred into corresponding microplates, and marked for differentiation; The heart failure analysis in step S3 is to treat the nppb:luc strain zebrafish with drugs until 72 hpf, add luciferase reagent to each well of the microplate, incubate in the dark, measure the luciferase value, and observe the expression level of the heart failure marker gene nppb; The analysis of heart development in step S4 is to treat cmlc2:GFP strain zebrafish with drugs until 72 hpf, anesthetize the zebrafish, and observe the heart morphology of the zebrafish under a fluorescence microscope.

2. A method for constructing a zebrafish heart failure model according to claim 1, It is characterized in that The drug treatment group was prepared by dissolving AA powder with DMSO solution to prepare a 10 mM AA stock concentration, taking 1 μL of 10 mM AA and adding it to a zebrafish microplate containing 1 mL of fish water, and treating zebrafish with the drug. At this time, the treatment concentration of the drug AA was 10 μM.

3. The method for constructing a zebrafish heart failure model according to claim 1, It is characterized in that The control group was treated with DMSO solution of the same concentration as that of the drug-treated group.

4. The method for constructing a zebrafish heart failure model according to claim 1, It is characterized in that The drug-treated group and the control group were both added with the same volume of fish culture water and cultured at the same constant temperature.

5. The method for constructing a zebrafish heart failure model according to claim 1, It is characterized in that The step S5 analyzing the survival rate is to observe the heartbeat of the zebrafish under a microscope after treating the cmlc2:GFP strain zebrafish with drugs to 96 hpf, and to calculate the survival rate of the zebrafish.

6. A detection method for constructing a zebrafish heart failure model according to any one of claims 1 to 5, It is characterized in that The detection method: T1, cmlc2:GFP zebrafish were treated with drugs until 72 hpf, and the zebrafish hearts were isolated; T2. Extract RNA, reverse transcribe it into cDNA, and then perform fluorescence quantitative PCR to detect the mRNA expression levels of heart failure marker genes nppa, nppb and IL-1β.